Abstract:Colorectal cancer (CRC) is one of the deadliest malignant tumors worldwide and its prevalence is increasing in South Korea. The efficacy of combined treatment with natural product‑derived and chemotherapy agents including curcumin combined with 5‑fluorouracil, resveratrol combined with cisplatin and epigallocatechin‑3‑gallate (EGCG) combined with cisplatin in preventing cancer progression and killing cancer cells has emerged. The Akt and Hippo signaling pathways serve a key role in colorectal tumor growth; however, the exact role of the crosstalk between Akt and Hippo signaling pathways in CRC remains poorly elucidated. The combined effect of UA and DOX on the cell proliferation, apoptosis, migration and cell cycle of CRC cells were investigated by performing Cell proliferation assay, a soft agar colony formation assay, flow cytometry, wound healing assay and western blotting assay. Subsequently, the expression of AKT and Hippo signaling pathway‑associated proteins were also assessed by western blot assay. Moreover, a xenograft nude mouse model was constructed to verify the effects of UA and DOX on the tumorigenesis of HCT116 cell in vivo. The present study reported that ursolic acid (UA) strongly enhanced the antitumor action of doxorubicin (DOX) via blocking the Akt/glycogen synthase kinase‑3β (Gsk3β) signaling pathway and activating tumor‑suppressive Hippo signaling (mammalian Ste20‑like kinase 1 and 2, salvador family WW domain containing protein 1 and MOB kinase activator 1), thereby downregulating downstream effector yes‑associated protein 1 (Yap) and connective tissue growth factor (CTGF) protein expression levels in CRC cells. Furthermore, The PI3K inhibitor LY294002 further suppressed Akt activity and enhance the function of Hippo pathway‑associated proteins in DOX + UA treated cells; this effect led to subsequent oncogenic Yap and CTGF inhibition following combined treatment, whereas Akt activator SC79 exerted an opposite effect in CTGF expression. In vivo, treatment with UA combined with DOX markedly suppressed the progression of CRC without any toxic effects on a xenograft mouse model by disrupting Akt signaling and activating the Hippo signaling pathway. These results demonstrated that UA and DOX treatment successfully induced Akt/Gsk3β inactivation via Hippo signaling pathway activation to promote Yap degradation, resulting in the inhibition of colorectal tumorigenesis. In conclusion, these findings suggested that combination therapy with UA and DOX may be more effective than DOX alone. UA may be a novel anticancer strategy and could be considered for investigation as a complementary chemotherapy agent in the future.

Ursolic acid inhibits colorectal cancer angiogenesis through suppression of multiple signaling pathways

Ursolic Acid Inhibits Epithelial-Mesenchymal Transition through the Axl/NF- κ B Pathway in Gastric Cancer Cells.

The Analysis of the Anti-Tumor Mechanism of Ursolic Acid Using Connectively Map Approach in Breast Cancer Cells Line MCF-7

Ursolic Acid Simultaneously Targets Multiple Signaling Pathways To Suppress Proliferation And Induce Apoptosis In Colon Cancer Cells

Mechanistic study on ursolic acid inhibiting the growth of colorectal cancer cells through the downregulation of TGF‐β3 by miR‐140‐5p

Usnic Acid Inhibits Breast Tumor Angiogenesis and Growth by Suppressing VEGFR2-mediated AKT and ERK1/2 Signaling Pathways

Ursolic acid in colorectal cancer: mechanisms, current status, challenges, and future research directions

Ursolic acid inhibits the activation of smoothened‐independent non‐canonical hedgehog pathway in colorectal cancer by suppressing AKT signaling cascade

Ursolic acid inhibits the metastasis of colon cancer by downregulating ARL4C expression

Ursolic Acid Inhibits Proliferation and Induces Apoptosis of Cancer Cells in Vitro and in Vivo

Inhibition of colorectal cancer tumorigenesis by ursolic acid and doxorubicin is mediated by targeting the Akt signaling pathway and activating the Hippo signaling pathway

Inhibitory Effects of Ursolic Acid on the Stemness and Progression of Human Breast Cancer Cells by Modulating Argonaute-2

Ursolic Acid Inhibits Glioblastoma Through Suppressing TGFβ-mediated Epithelial-Mesenchymal Transition (EMT) and Angiogenesis

Hypoxia Pathway and Hypoxia-Mediated Extensive Extramedullary Hematopoiesis Are Involved in Ursolic Acid'S Anti-Metastatic Effect in 4t1 Tumor Bearing Mice

Ursolic Acid Inhibits Gastric Cancer Cells Proliferation through AMPK/STAT3/COX-2 Signaling Pathway

Ursolic acid inhibits growth and induces apoptosis in gemcitabine-resistant human pancreatic cancer via the JNK and PI3K/Akt/NF-κB pathways.

Urolithin C suppresses colorectal cancer progression via the AKT/mTOR pathway

Ursolic Acid Promotes Cancer Cell Death by Inducing Atg5‐dependent Autophagy

Ursolic Acid Inhibits Glycolysis of Ovarian Cancer via KLF5/PI3K/AKT Signaling Pathway

Ursolic Acid Inhibits Breast Cancer Metastasis by Suppressing Glycolytic Metabolism via Activating SP1/Caveolin-1 Signaling

Ursolic acid regulates key EMT transcription factors, induces cell cycle arrest and apoptosis in MDA-MB-231 and MCF-7 breast cancer cells, an in-vitro and in silico studies